In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Inovio Pharmaceuticals Inc (NASDAQ:INO) with a $20 price …
In a research report issued Monday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on shares of Neuralstem, Inc. (NYSE MKT:CUR), with an $8.
The first quarter of 2015 has come to a close and companies are still releasing earnings reports. Let’s look back and see which …
Brean Capital analyst Jonathan Aschoff came out with a few insights on Celldex Therapeutics (NASDAQ:CLDX) following the company’s first-quarter financial results and update on its …
In a research report released Tuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) with an $8.00 price …
Brean Capital’s analyst Jonathan Aschoff came out today with a research note on Recro Pharma Inc (NASDAQ:REPH), maintaining a price target of $26 …
Brean Capital analyst Jonathan Aschoff weighed in today with a few insights on IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), after the company provided an update on the progress of the product …
In a research report released Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) with a $34 …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Soligenix Inc (OTCBB:SNGX) with a price target of $5 …
Brean Capital analyst Jonathan Aschoff weighed in today with a few insights on Nektar Therapeutics (NASDAQ:NKTR), following the news that AstraZeneca plc (ADR) (NYSE:AZN) will commercialize Movantik in the US jointly …
